Lexicon Pharmaceuticals LXRX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Lexicon Pharmaceuticals (LXRX) Business Model and Operations Summary
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Key Insights
Lexicon Pharmaceuticals (LXRX) Core Market Data and Business Metrics
Latest Closing Price
$0.4641Market Cap
$170.34 MillionPrice-Earnings Ratio
-0.74Total Outstanding Shares
361.49 Million SharesTotal Employees
285Dividend
No dividendIPO Date
April 7, 2000SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
2445 Technology Forest Blvd., The Woodlands, TX, 77381
Historical Stock Splits
If you bought 7 shares of LXRX before May 21, 2015, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| May 21, 2015 | 1-for-7 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $44.19 Million |
| Net Cash Flow From Financing Activities, Continuing | $238.35 Million |
| Net Cash Flow From Operating Activities | $-178.78 Million |
| Net Cash Flow From Investing Activities, Continuing | $-15.38 Million |
| Net Cash Flow From Financing Activities | $238.35 Million |
| Net Cash Flow From Operating Activities, Continuing | $-178.78 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss | $-200.40 Million |
| Costs And Expenses | $228.20 Million |
| Diluted Average Shares | $320.03 Million |
| Operating Income/Loss | $-197.12 Million |
| Basic Average Shares | $320.03 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-200.31 Million |
| Comprehensive Income/Loss | $-200.31 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-200.31 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Inventory | $231,000 |
| Noncurrent Assets | $52.23 Million |
| Noncurrent Liabilities | $107.22 Million |
| Equity Attributable To Parent | $145.95 Million |
| Equity | $145.95 Million |
| Current Liabilities | $45.25 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||